250 related items for PubMed ID: 30173205
21. Longitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients.
Van der Kamp HJ, Otten BJ, Buitenweg N, De Muinck Keizer-Schrama SM, Oostdijk W, Jansen M, Delemarre-de Waal HA, Vulsma T, Wit JM.
Arch Dis Child; 2002 Aug; 87(2):139-44. PubMed ID: 12138066
[Abstract] [Full Text] [Related]
22. Do All Patients with Congenital Adrenal Hyperplasia Need to Be on Hydrocortisone Three Times a Day in Order to Have Normal Growth?
Logan LA, Nebesio TD, Eckert GJ, Eugster EA.
Horm Res Paediatr; 2022 Aug; 95(5):461-464. PubMed ID: 35649383
[Abstract] [Full Text] [Related]
23. Indicators of adult height outcome in classical 21-hydroxylase deficiency congenital adrenal hyperplasia.
Muirhead S, Sellers EA, Guyda H, Canadian Pediatric Endocrine Group.
J Pediatr; 2002 Aug; 141(2):247-52. PubMed ID: 12183722
[Abstract] [Full Text] [Related]
24. Monitoring treatment in congenital adrenal hyperplasia.
Appan S, Hindmarsh PC, Brook CG.
Arch Dis Child; 1989 Sep; 64(9):1235-9. PubMed ID: 2640553
[Abstract] [Full Text] [Related]
25. Long-term Growth in Congenital Adrenal Hyperplasia.
Maheshwari A, Khadilkar V, Gangodkar P, Khadilkar A.
Indian J Pediatr; 2019 Feb; 86(2):154-158. PubMed ID: 30097840
[Abstract] [Full Text] [Related]
26. Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty.
Bonfig W, Bechtold S, Schmidt H, Knorr D, Schwarz HP.
J Clin Endocrinol Metab; 2007 May; 92(5):1635-9. PubMed ID: 17299071
[Abstract] [Full Text] [Related]
27. Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia.
Merke DP, Keil MF, Jones JV, Fields J, Hill S, Cutler GB.
J Clin Endocrinol Metab; 2000 Mar; 85(3):1114-20. PubMed ID: 10720048
[Abstract] [Full Text] [Related]
28. Patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency can achieve their target height: the Leipzig experience.
Hoepffner W, Kaufhold A, Willgerodt H, Keller E.
Horm Res; 2008 Mar; 70(1):42-50. PubMed ID: 18493149
[Abstract] [Full Text] [Related]
29. Congenital Adrenal Hyperplasia in Children: The Relationship between Plasma Renin Activity and Hypertension.
Lubis SM, Soesanti F, Hidayati EL, Aap BT.
Iran J Med Sci; 2024 Jun; 49(6):377-383. PubMed ID: 38952640
[Abstract] [Full Text] [Related]
30. Management of the child with congenital adrenal hyperplasia.
Hindmarsh PC.
Best Pract Res Clin Endocrinol Metab; 2009 Apr; 23(2):193-208. PubMed ID: 19500763
[Abstract] [Full Text] [Related]
31. A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia.
Laue L, Merke DP, Jones JV, Barnes KM, Hill S, Cutler GB.
J Clin Endocrinol Metab; 1996 Oct; 81(10):3535-9. PubMed ID: 8855797
[Abstract] [Full Text] [Related]
32. Molecular testing in congenital adrenal hyperplasia due to 21α-hydroxylase deficiency in the era of newborn screening.
Sarafoglou K, Lorentz CP, Otten N, Oetting WS, Grebe SK.
Clin Genet; 2012 Jul; 82(1):64-70. PubMed ID: 21534945
[Abstract] [Full Text] [Related]
33. [Comparative study of prednisolone versus hydrocortisone acetate for treatment of patients with the classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency].
Leite FM, Longui CA, Kochi C, Faria CD, Borghi M, Calliari LE, Monte O.
Arq Bras Endocrinol Metabol; 2008 Feb; 52(1):101-8. PubMed ID: 18345402
[Abstract] [Full Text] [Related]
34. Modified-release hydrocortisone is associated with lower plasma renin activity in patients with salt-wasting congenital adrenal hyperplasia.
Tschaidse L, Reisch N, Arlt W, Brac de la Perriere A, Linden Hirschberg A, Juul A, Mallappa A, Merke DP, Newell-Price JDC, Perry CG, Prete A, Rees DA, Stikkelbroeck NMML, Touraine PA, Coope H, Porter J, Ross RJM, Quinkler M.
Eur J Endocrinol; 2023 Jan 10; 188(1):. PubMed ID: 36654495
[Abstract] [Full Text] [Related]
35. Growth patterns and outcomes in congenital adrenal hyperplasia; effect of chronic treatment regimens.
Rasat R, Espiner EA, Abbott GD.
N Z Med J; 1995 Aug 11; 108(1005):311-4. PubMed ID: 7644165
[Abstract] [Full Text] [Related]
36. Bone Mass in Young Patients with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency.
Espinosa Reyes TM, Leyva González G, Domínguez Alonso E, Falhammar H.
Horm Res Paediatr; 2021 Aug 11; 94(1-2):1-8. PubMed ID: 34044395
[Abstract] [Full Text] [Related]
37. Final height of patients with classical congenital adrenal hyperplasia.
Aycan Z, Akbuğa S, Cetinkaya E, Ocal G, Berberoğlu M, Evliyaoğlu O, Adiyaman P.
Turk J Pediatr; 2009 Aug 11; 51(6):539-44. PubMed ID: 20196386
[Abstract] [Full Text] [Related]
38. Serum leptin levels in patients with 21-hydroxylase deficiency before and after treatment.
Poyrazoglu S, Günöz H, Darendeliler F.
Turk J Pediatr; 2003 Aug 11; 45(1):33-8. PubMed ID: 12718369
[Abstract] [Full Text] [Related]
39. Synthetic glucocorticoids instead of hydrocortisone do not increase mineralocorticoid needs in adult patients with salt wasting congenital adrenal hyperplasia.
Auer MK, Paizoni L, Nowotny H, Lottspeich C, Tschaidse L, Schmidt H, Bidlingmaier M, Reisch N.
J Steroid Biochem Mol Biol; 2023 Jun 11; 230():106271. PubMed ID: 36764494
[Abstract] [Full Text] [Related]
40. Diagnosis and management of classical congenital adrenal hyperplasia.
Marumudi E, Khadgawat R, Surana V, Shabir I, Joseph A, Ammini AC.
Steroids; 2013 Aug 11; 78(8):741-6. PubMed ID: 23624029
[Abstract] [Full Text] [Related]
Page: [Previous] [Next] [New Search]
